Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study

Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study

To evaluate the efficacy of tafasitamab in patients with relapsed/ refractory diffuse large B-cell lymphoma

*To evaluate best objective response rate (ORR)

Inclusion Criteria:

1. Adult patients aged ≥18 years at the time of tafasitamab initiation.
2. Patients who were initiated on tafasitamab treatment between August 1, 2024, and December 31, 2028.
3. Patients with a histologically confirmed diagnosis of DLBCL.
4. Patients ineligible for ASCT based on clinical judgment, comorbidities, or other relevant factors.
5. Patients must have relapsed or refractory disease following at least one prior systemic regimen for DLBCL, with at least one line of therapy including a CD20-targeted agent (e.g., rituximab).

Exclusion Criteria:

1. Patients who are alive but unable or unwilling to provide written informed consent.

-